136 related articles for article (PubMed ID: 36763100)
1. Therapeutic potential of FLT4-targeting peptide in acute myeloid leukemia.
Lee JY; Park S; Han AR; Hwang HS; Kim HJ
Cancer Immunol Immunother; 2023 Sep; 72(9):2919-2925. PubMed ID: 36763100
[TBL] [Abstract][Full Text] [Related]
2. A VEGFR-3 antagonist increases IFN-γ expression on low functioning NK cells in acute myeloid leukemia.
Lee JY; Park S; Kim DC; Yoon JH; Shin SH; Min WS; Kim HJ
J Clin Immunol; 2013 May; 33(4):826-37. PubMed ID: 23404187
[TBL] [Abstract][Full Text] [Related]
3. Peptides Targeting Fms-Related Tyrosine Kinase-4 Activate the Function of Natural Killer Cells in Acute Myeloid Leukemia.
Park S; Kim HJ; Hwang HS; Han AR
Int J Stem Cells; 2021 Nov; 14(4):400-409. PubMed ID: 34158419
[TBL] [Abstract][Full Text] [Related]
4. FLT4 as a marker for predicting prognostic risk of refractory acute myeloid leukemia.
Lee JY; Lee SE; Han AR; Lee J; Yoon YS; Kim HJ
Haematologica; 2023 Nov; 108(11):2933-2945. PubMed ID: 37317880
[TBL] [Abstract][Full Text] [Related]
5. Acute myeloid leukemic cell lines loaded with synthetic dsRNA trigger IFN-gamma secretion by human NK cells.
Lion E; Smits EL; Berneman ZN; Van Tendeloo VF
Leuk Res; 2009 Apr; 33(4):539-46. PubMed ID: 18845337
[TBL] [Abstract][Full Text] [Related]
6. Expression of FLT4 and its ligand VEGF-C in acute myeloid leukemia.
Fielder W; Graeven U; Ergün S; Verago S; Kilic N; Stockschläder M; Hossfeld DK
Leukemia; 1997 Aug; 11(8):1234-7. PubMed ID: 9264375
[TBL] [Abstract][Full Text] [Related]
7. Selective targeting of human lymphokine-activated killer cells by CD3 monoclonal antibody against the interferon-inducible high-affinity Fc gamma RI receptor (CD64) on autologous acute myeloid leukemic blast cells.
Notter M; Ludwig WD; Bremer S; Thiel E
Blood; 1993 Nov; 82(10):3113-24. PubMed ID: 7693036
[TBL] [Abstract][Full Text] [Related]
8. Blockade of FLT4 suppresses metastasis of melanoma cells by impaired lymphatic vessels.
Lee JY; Hong SH; Shin M; Heo HR; Jang IH
Biochem Biophys Res Commun; 2016 Sep; 478(2):733-8. PubMed ID: 27507214
[TBL] [Abstract][Full Text] [Related]
9. Activated NK cells reprogram MDSCs via NKG2D-NKG2DL and IFN-γ to modulate antitumor T-cell response after cryo-thermal therapy.
Peng P; Lou Y; Wang S; Wang J; Zhang Z; Du P; Zheng J; Liu P; Xu LX
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36521929
[TBL] [Abstract][Full Text] [Related]
10. Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia.
Caruso S; De Angelis B; Del Bufalo F; Ciccone R; Donsante S; Volpe G; Manni S; Guercio M; Pezzella M; Iaffaldano L; Silvestris DA; Sinibaldi M; Di Cecca S; Pitisci A; Velardi E; Merli P; Algeri M; Lodi M; Paganelli V; Serafini M; Riminucci M; Locatelli F; Quintarelli C
J Hematol Oncol; 2022 Nov; 15(1):163. PubMed ID: 36335396
[TBL] [Abstract][Full Text] [Related]
11. Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia.
Stringaris K; Sekine T; Khoder A; Alsuliman A; Razzaghi B; Sargeant R; Pavlu J; Brisley G; de Lavallade H; Sarvaria A; Marin D; Mielke S; Apperley JF; Shpall EJ; Barrett AJ; Rezvani K
Haematologica; 2014 May; 99(5):836-47. PubMed ID: 24488563
[TBL] [Abstract][Full Text] [Related]
12. Restoration of natural killer cell cytotoxicity by VEGFR-3 inhibition in myelogenous leukemia.
Lee JY; Park S; Min WS; Kim HJ
Cancer Lett; 2014 Nov; 354(2):281-9. PubMed ID: 25157650
[TBL] [Abstract][Full Text] [Related]
13. Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemia.
Mani R; Rajgolikar G; Nunes J; Zapolnik K; Wasmuth R; Mo X; Byrd JC; Lee DA; Muthusamy N; Vasu S
Cytotherapy; 2020 Jul; 22(7):369-376. PubMed ID: 32303428
[TBL] [Abstract][Full Text] [Related]
14. Significance of Frequencies, Compositions, and/or Antileukemic Activity of (DC-stimulated) Invariant NKT, NK and CIK Cells on the Outcome of Patients With AML, ALL and CLL.
Boeck CL; Amberger DC; Doraneh-Gard F; Sutanto W; Guenther T; Schmohl J; Schuster F; Salih H; Babor F; Borkhardt A; Schmetzer H
J Immunother; 2017; 40(6):224-248. PubMed ID: 28557814
[TBL] [Abstract][Full Text] [Related]
15. Cyclosporine-induced autologous graft-versus-host disease in patients with acute myeloid leukemia undergoing non-myeloablative chemotherapy without progenitor cell reinfusion.
Stein M; Feldman E; Seiter K; Chiao JW; Goff H; Baskind P; Beer M; Ahmed T
Bone Marrow Transplant; 1999 Nov; 24(10):1073-7. PubMed ID: 10578157
[TBL] [Abstract][Full Text] [Related]
16. Chronic IL-15 Stimulation and Impaired mTOR Signaling and Metabolism in Natural Killer Cells During Acute Myeloid Leukemia.
Bou-Tayeh B; Laletin V; Salem N; Just-Landi S; Fares J; Leblanc R; Balzano M; Kerdiles YM; Bidaut G; Hérault O; Olive D; Aurrand-Lions M; Walzer T; Nunès JA; Fauriat C
Front Immunol; 2021; 12():730970. PubMed ID: 34975835
[TBL] [Abstract][Full Text] [Related]
17. Higher PD-1/Tim-3 expression on IFN-γ+ T cells is associated with poor prognosis in patients with acute myeloid leukemia.
Huang S; Zhao Y; Lai W; Tan J; Zheng X; Zha X; Li Y; Chen S
Cancer Biol Ther; 2023 Dec; 24(1):2278229. PubMed ID: 37962843
[TBL] [Abstract][Full Text] [Related]
18. Receptor activator for NF-κB ligand in acute myeloid leukemia: expression, function, and modulation of NK cell immunosurveillance.
Schmiedel BJ; Nuebling T; Steinbacher J; Malinovska A; Wende CM; Azuma M; Schneider P; Grosse-Hovest L; Salih HR
J Immunol; 2013 Jan; 190(2):821-31. PubMed ID: 23241893
[TBL] [Abstract][Full Text] [Related]
19. Human CD80/IL2 lentivirus transduced acute myeloid leukaemia cells enhance cytolytic activity in vitro in spite of an increase in regulatory CD4+ T cells in a subset of cultures.
Ingram W; Kordasti S; Chan L; Barber LD; Tye GJ; Hardwick N; Mufti GJ; Farzaneh F
Cancer Immunol Immunother; 2009 Oct; 58(10):1679-90. PubMed ID: 19283381
[TBL] [Abstract][Full Text] [Related]
20. Defective NK Cells in Acute Myeloid Leukemia Patients at Diagnosis Are Associated with Blast Transcriptional Signatures of Immune Evasion.
Khaznadar Z; Boissel N; Agaugué S; Henry G; Cheok M; Vignon M; Geromin D; Cayuela JM; Castaigne S; Pautas C; Raffoux E; Lachuer J; Sigaux F; Preudhomme C; Dombret H; Dulphy N; Toubert A
J Immunol; 2015 Sep; 195(6):2580-90. PubMed ID: 26246143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]